Cases & Deals

  • Home
  • Practices
  • GlycoVaxyn builds bioconjugate vaccine patent portfolio

Share

GlycoVaxyn builds bioconjugate vaccine patent portfolio

September 2008

Clients GlycoVaxyn AG

Jones Day represents GlycoVaxyn AG in developing its patent portfolio and prosecution strategies relating to next-generation bioconjugate vaccines, including methods for production of the vaccines using in vivo systems.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.